TheEdgeResearch
Home / Stocks / RARE

Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ Healthcare Biotechnology
$22.79 ▲ +5.56%
Market Cap
$2.24B
Sector
Healthcare
Industry
Biotechnology
Beta
0.38
52-Wk Range
18.29-42.37
CEO
Emil D. Kakkis
Country
US
Currency
USD

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients sufferin…

Open full interactive analysis & DCF →